This finding supported the hypothesis that ABCB5+ D-MSCs might provide therapeutic benefit in RDEB through a C7-independent pathway in contrast to previous work on BM-MSCs. Here, ABCB5 is linked to recessive dystrophic epidermolysis bullosa.